Regenxbio Inc. (FWB:RB0) Financings

Regenxbio Inc.

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Closed: US$108M raised · US$9 a share · Morgan Stanley +3
Dealers: Morgan Stanley (co-lead), J.P. Morgan (co-lead), Leerink Partners (co-lead), Mizuho (co-lead)
Use of proceeds: Extend cash runway into Q4 2027 and support the planned AFFINITY RISE ex-U.S. randomized-controlled trial of RGX-202 in 1H 2027
Aug 6, 2026
Limited recourse royalty bond with warrants
Tranche closed: US$150M raised · Warrants at US$14.92
Buyers: Healthcare Royalty (HCRx) (up to $250 million bond; $150 million funded at closing, plus warrants for up to 268,096 shares)
Use of proceeds: Extend cash runway into early 2027 and fund late-stage activities and commercial preparations
May 19, 2025

Read by 6ix AI from the company's releases